Q&A: HDV Management Episode 2
Hepatitis Delta in Focus: Episode 2 of Answering the Questions on Screening, Diagnosis, and Treatment

Released: April 27, 2023

Tatyana Kushner
Tatyana Kushner, MD, MSCE
Stefan Zeuzem
Stefan Zeuzem, MD

Activity

Progress
1
Course Completed

In this episode, Tatyana Kushner, MD, MSCE, and Stefan Zeuzem, MD, address key considerations when screening, diagnosing, and treating patients with HDV, such as:

  • Barriers to HDV screening, including limitations to AASLD guideline recommendations
  • Use of double reflex testing to improve HDV diagnosis
  • Considerations for repeat HDV testing in patients who are HBsAg positive who previously tested negative for HDV
  • Updated CDC recommendations for HBV screening for all adults using a triple panel test
  • Staging advanced liver disease in patients with HDV
  • Indications for HDV treatment, including patients with low ALT levels and advanced or progressive liver disease
  • Treatment landscape for HDV
  • Personal experiences with use of pegylated interferon for HDV treatment, including considerations for use in patients with compensated cirrhosis
  • Updates on novel HDV therapies, including:
    • Summary of efficacy data on bulevirtide from clinical trials
    • Interpretation of results from D-LIVR, a phase III trial assessing the safety and efficacy of lonafarnib